Samantha Tauchmann

Samantha Tauchmann

Auto-generated profile, based on publicly available information

Samantha Tauchmann

Oregon Health & Science University 1 Division of Oncological Sciences, Knight Cancer Institute Portland, Oregon

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in Blood
Verified
Journal Article
Open access
PDF file
AFAlexandre Fagnan
Alexandre Fagnan
FBFrederik Otzen Bagger
Frederik Otzen Bagger
MPMaria-Riera Piqué-Borràs
Maria-Riera Piqué-Borràs
CICathy Ignacimouttou
Cathy Ignacimouttou
ACAlexis Caulier
Alexis Caulier
TMThomas Mercher
Thomas Mercher
Acute erythroleukemia (AEL or acute myeloid leukemia [AML]-M6) is a rare but aggressive hematologic malignancy. Previous studies showed that AEL leukemic cells often carry complex karyotypes and mutations in known AML-associated oncogenes. To better define the underlying molecular mechanisms driving the erythroid phenotype, we studied a series of 33 AEL samples representing 3 genetic AEL subgroups including TP53-mutated, epigenetic regulator-mutated (eg, DNMT3A, TET2, or IDH2), and undefined cases with low mutational burden. We established an erythroid vs myeloid transcriptome-based space in which, independently of the molecular subgroup, the majority of the AEL samples exhibited a unique mapping different from both non-M6 AML and myelodysplastic syndrome samples. Notably, >25% of AEL patients, including in the genetically undefined subgroup, showed aberrant expression of key transcriptional regulators, including SKI, ERG, and ETO2. Ectopic expression of these factors in murine erythroid progenitors blocked in vitro erythroid differentiation and led to immortalization associated with decreased chromatin accessibility at GATA1-binding sites and functional interference with GATA1 activity. In vivo models showed development of lethal erythroid, mixed erythroid/myeloid, or other malignancies depending on the cell population in which AEL-associated alterations were expressed. Collectively, our data indicate that AEL is a molecularly heterogeneous disease with an erythroid identity that results in part from the aberrant activity of key erythroid transcription factors in hematopoietic stem or progenitor cells.

12 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KLKatharina Leonards
Katharina Leonards
MAMarwa Almosailleakh
Marwa Almosailleakh
STSamantha Tauchmann
Samantha Tauchmann
FBFrederik Otzen Bagger
Frederik Otzen Bagger
CTCécile Thirant
Cécile Thirant
JSJuerg Schwaller
Juerg Schwaller
The nuclear receptor binding SET domain protein 1 (NSD1) is recurrently mutated in human cancers including acute leukemia. We show that NSD1 knockdown alters erythroid clonogenic growth of human CD34+hematopoietic cells. Ablation ofNsd1in the hematopoietic system of mice induces a transplantable erythroleukemia. In vitro differentiation ofNsd1−/−erythroblasts is majorly impaired despite abundant expression of GATA1, the transcriptional master regulator of erythropoiesis, and associated with an impaired activation of GATA1-induced targets. Retroviral expression of wildtype NSD1, but not a catalytically-inactive NSD1N1918QSET-domain mutant induces terminal maturation ofNsd1−/−erythroblasts. Despite similar GATA1 protein levels, exogenous NSD1 but not NSDN1918Qsignificantly increases the occupancy of GATA1 at target genes and their expression. Notably, exogenous NSD1 reduces the association of GATA1 with the co-repressor SKI, and knockdown of SKI induces differentiation ofNsd1−/−erythroblasts. Collectively, we identify the NSD1 methyltransferase as a regulator of GATA1-controlled erythroid differentiation and leukemogenesis.

25 August 2021 in Life
Verified
Journal Article
Open access
PDF file
STSamantha Tauchmann
Samantha Tauchmann
JSJuerg Schwaller
Juerg Schwaller
Recurrent epigenomic alterations associated with multiple human pathologies have increased the interest in the nuclear receptor binding SET domain protein 1 (NSD1) lysine methyltransferase. Here, we review the current knowledge about the biochemistry, cellular function and role of NSD1 in human diseases. Several studies have shown that NSD1 controls gene expression by methylation of lysine 36 of histone 3 (H3K36me1/2) in a complex crosstalk with de novo DNA methylation. Inactivation in flies and mice revealed that NSD1 is essential for normal development and that it regulates multiple cell type-specific functions by interfering with transcriptional master regulators. In humans, putative loss of function NSD1 mutations characterize developmental syndromes, such as SOTOS, as well as cancer from different organs. In pediatric hematological malignancies, a recurrent chromosomal translocation forms a NUP98-NSD1 fusion with SET-dependent leukemogenic activity, which seems targetable by small molecule inhibitors. To treat or prevent diseases driven by aberrant NSD1 activity, future research will need to pinpoint the mechanistic correlation between the NSD1 gene dosage and/or mutational status with development, homeostasis, and malignant transformation.

28 March 2025 in Blood Advances
Verified
Journal Article
Open access
Lucie DarmuseyLucie Darmusey
Lucie Darmusey
ABAnna J. Bagley
Anna J. Bagley
TNThai T. Nguyen
Thai T. Nguyen
HCHanqian L. Carlson
Hanqian L. Carlson
HBHunter Blaylock
Hunter Blaylock
JMJulia E. Maxson
Julia E. Maxson
Mutations in the epigenetic regulator Additional Sex Combs-Like 1 (ASXL1) are frequently observed in chronic neutrophilic leukemia (CNL). CNL is a myeloproliferative neoplasm (MPN) driven by activating mutations in the Colony Stimulating Factor 3 Receptor (CSF3R), which cause excessive neutrophil production. Despite the high rates of co-occurrence, the interplay between ASXL1 and CSF3R mutations in hematopoiesis and leukemia remains poorly understood. Here, we present a new mouse model with both Asxl1Y588X and Csf3rT621I mutations, which recapitulates features of human MPNs. Csf3r-mutant mice exhibit an age-associated depletion of hematopoietic stem cells, which is tempered by adding Asxl1Y588X. This combination of mutations causes an expansion of myeloid-biased long-term hematopoietic stem cells. As the mice age, they develop neutrophilia, but leukemia is rare, suggesting additional mutations may be required for transformation. Using models of myeloid differentiation, we find that Asxl1 truncation enhances CSF3RT618I-driven neutrophil differentiation, activating inflammatory pathways associated with mature myeloid cell production. Moreover, cells with both mutations have increased H3K4me1 at neutrophil-associated enhancers. Mutant ASXL1 is known to decrease the genome-wide abundance of the repressive histone mark H2AK119ub. Although we see the expected decrease in H2AK119ub in Asxl1-mutant cells, this effect is reversed when CSF3R is also mutated, suggesting a complex interplay between these mutations in regulating chromatin dynamics during hematopoiesis. Our findings highlight context-dependent effects of ASXL1 mutation in myeloid disorders and provide insights into the mechanisms underlying neutrophil differentiation in ASXL1 and CSF3R dual-mutant MPN.

14 September 2020 in Molecular & Cellular Oncology
Verified
Journal Article
Open access
STSamantha Tauchmann
Samantha Tauchmann
MAMarwa Almosailleakh
Marwa Almosailleakh
JSJuerg Schwaller
Juerg Schwaller
We have uncovered a novel role for the nuclear receptor-binding SET domain protein 1 (NSD1) in human and murine erythroid differentiation. Mechanistically, we found that the histone methyltransferase activity of NSD1 is essential for chromatin binding, protein interactions and target gene activation of the erythroid transcriptional master regulator GATA1.

3 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
ECEmil Chteinberg
Emil Chteinberg
DRDorit Rennspiess
Dorit Rennspiess
RSRyan Sambo
Ryan Sambo
STSamantha Tauchmann
Samantha Tauchmann
NKNicole W.J. Kelleners-Smeets
Nicole W.J. Kelleners-Smeets
AHAxel zur Hausen
Axel zur Hausen
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Emil Chteinberg1, 2, 3, Dorit Rennspiess1, Ryan Sambo1, Samantha Tauchmann1, Nicole W.J. Kelleners-Smeets4, Véronique Winnepenninckx1, Ernst-Jan Speel1, Anna Kordelia Kurz5, Martin Zenke2, 3 and Axel zur Hausen1 1Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands 2Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Hospital, Aachen, Germany 3Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany 4Department of Dermatology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands 5Department of Internal Medicine IV, RWTH Aachen University Hospital, Aachen, Germany Correspondence to: Axel zur Hausen, email: axel.zurhausen@mumc.nl Keywords: Merkel cell carcinoma; phosphatidylinositol 3-kinase; chemotherapeutics Received: February 05, 2018 Accepted: May 31, 2018 Published: July 03, 2018 ABSTRACT The prognosis of stage III/IV Merkel cell carcinoma (MCC) is very poor. The Phosphatidylinositol 3-kinase p110δ specific inhibitor idelalisib has recently been reported to induce complete clinical remission in a stage IV MCC patient. Here we assessed the expression of p110δ in primary MCC and MCC cell lines including its functionality. Immunofluorescence microscopy revealed a specific cytoplasmic p110δ expression in 71.4% of the tested MCCs and in all tested MCC cell lines. Compared to the B cell leukemia cell line REH all MCC cell lines, except MKL-1, revealed a lower response towards the treatment with idelalisib. MKL-1 showed a 10-fold higher IC50 compared to REH which was accompanied by a significant decrease of Akt phosphorylation. However, treating the MCC cells with the specific PI3K p110α subunit inhibitor BYL719 led to a more effective decrease of the cell viability compared to idelalisib: WaGa cells 30-fold, PeTa cells 15-fold and all other MCC cell lines 3-fold. Although PI3K p110δ is expressed in the majority of MCCs and cell lines its inhibition by idelalisib alone does not suffice to effectively affect MCC cells viability.